Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | P4HB | P07237 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11928250 | 0.87 | ALDH1A1 (0.49) | ALDH1A1KDM4ECYP3A4CYP2C19TSHR | |
| SCHEMBL5182185 | 0.86 | LMNA (0.69) | ALDH1A1LMNAGAATSHRACHE | |
| Hydrochloric Acid SCHEMBL8842731 | 0.86 | ALDH1A1 (0.51) | ALDH1A1LMNAKDM4ECYP3A4CYP2C19 | |
| SCHEMBL2171115 | 0.85 | GAA (0.70) | ALDH1A1LMNAGAATSHRACHE | |
| SCHEMBL627906 | 0.84 | ALDH1A1 (0.73) | ALDH1A1LMNAGAACYP3A4CYP2C19 | |
| SCHEMBL1706030 | 0.84 | ALDH1A1 (0.73) | ALDH1A1LMNAGAACYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL15063230 | 0.83 | GAA (0.73) | ALDH1A1LMNAGAAKDM4ETSHR | |
| SCHEMBL28261688 | 0.83 | ALDH1A1 (0.64) | ALDH1A1LMNAGAACYP3A4CYP2C19 | |
| SCHEMBL3236859 | 0.83 | ALDH1A1 (0.55) | ALDH1A1LMNAGAACYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL15063255 | 0.83 | ALDH1A1 (0.77) | ALDH1A1LMNAGAACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170172957-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-2714029-B1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9415031-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20140221453-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741955-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8735451-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120329851-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2012-12-27 | — | — | US | disclosed |
| WO-2012166533-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166544-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20120301729-A1 | TWO-COMPONENT ADHESIVE OR SEALANT COMPOSITION COMPRISING ACCELERATOR COMPONENT | SIKA TECHNOLOGY AG (CH) | 2012-11-29 | — | — | US | disclosed |
| US-20120302621-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| EP-1740553-A1 | ARYL GLYCINAMIDE DERIVATIVES AND THEIR USE AS NK1 ANTAGONISTS AND SEROTONIN REUPTAKE INHIBITHORS | AstraZeneca AB (SE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005100325-A1 | ARYL GLYCINAMIDE DERIVATIVES AND THEIR USE AS NK1 ANTAGONISTS AND SEROTONIN REUPTAKE INHIBITHORS | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | TPH1, NTSR1, HTR1D | ALDH1A1 254/4885LMNA 1764/4885GAA 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.